Lipocine Inc. LPCN
1.57 USD +0.04 (+2.61%)
At closeNov 6, 2026, 7:54 PM EST
1.57 0.00 -0.08%
After hours · Nov 6, 7:54 PM ET
1.50 Day range 1.63
1.44 52-week range 11.26
- YTD
- -80.45%
- 1 year
- -40.53%
News
benzinga.com Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per…
prnewswire.com Lipocine Announces Financial Results for the Third Quarter of 2026 SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results…
benzinga.com Nasdaq Falls Over 100 Points; US Crude Inventories Decline U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
benzinga.com Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
benzinga.com Dow Tumbles 350 Points; Constellation Brands Earnings Top Views U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
benzinga.com Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity…
benzinga.com HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.
benzinga.com Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41)…
benzinga.com Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26 Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno,…
benzinga.com CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35)…
benzinga.com What's Going On With Carvana Stock Monday? BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest analyst insights and technical support levels.
benzinga.com What's Going On With Lipocine Stock On Monday? Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.
benzinga.com This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed their outlook on top names. Check out the ratings page for complete changes. Check out what analysts think about CVNA.
benzinga.com Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Quarry Inc. and Cocrystal Pharma Inc. shares increase.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results for LPCN 1154 in postpartum depression.
benzinga.com Nasdaq Down 1%; US Initial Jobless Claims Fall US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer discretionary stocks fell. US jobless claims declined.- benzinga.com Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy Signals In Patients With Prior Psychiatric History And Maintains Favorable Safety Profile In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15 HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises the price target from $7 to $15.
benzinga.com Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Postpartum Depression Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment…
benzinga.com Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Ongoing Phase 3 Clinical Trial evaluating LPCN 1154 For Rapid Relief Treatment Of PPD. Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82…- benzinga.com Lipocine Granted U.S. Patent For Hydroxyprogesterone Caproate Compositions And Methods Of Use In Preventing Preterm Birth https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZjEtYmMzZi0wMDAyMTcyYjUyOTQiLCJ2ZXIiOiI5MzczYzJhZS0wZDkxLTQ4N2EtOGE3MC0xMmFkZTNhMmVhNTIiLCJleHAiOjB9
- benzinga.com Lipocine Nears Full Enrollment In Phase 3 PPD Trial, Topline Results Expected Q2 2026 Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine…
- benzinga.com Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Phase 3 Trial Of LPCN 1154 In Postpartum Depression Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as plannedMore than half of planned participants have completed dosing with no dose…
- benzinga.com HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7 HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers the price target from $8 to $7.
- benzinga.com Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by 8.26 percent. This is a 34.09 percent decrease over losses of $(0.44)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
- benzinga.com CORRECTION: Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849K Beat $229.000K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by 2.5 percent. This is a 26.79 percent increase over losses of $(0.56)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
- benzinga.com Lipocine Says Licensing Partner, Verity Pharma, Files New Drug Submission For TLANDO In Canada New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large…
- benzinga.com Lipocine's Licensing Partner, Verity Pharma, Filed A New Drug Submission For Tlando In Canada, Tlando Is The First And Only Oral Testosterone Replacement Therapy Option Approved By FDAThat Does Not Require Dose Titration New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large…
- benzinga.com HC Wainwright & Co. Assumes Lipocine at Buy, Announces Price Target of $8 HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $8.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. This is a 153.03 percent decrease over earnings of $0.66…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Lipocine Enters Into License And Supply Agreement With Aché Laboratórios Farmacêuitcos S.A Granting Exclusive Rights To Market Tlando in Brazil. Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Oral Delivery of Therapeutics, Today Announced That It Has Entered Into…
- benzinga.com Lipocine Announces Initiation Of A Phase 3 Trial For LPCN 1154 Which Is In Development For Treatment Of Postpartum Depression Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3…
- benzinga.com Lipocine Announces The Publication And Discussion Of A Manuscript "Oral LPCN 1148 Improves Sarcopenia And Hepatic Encephalopathy In Male Patients With Cirrhosis: A Randomized, Placebo-controlled Phase 2 Trial" In The Journal Hepatology And Discussion At The Liver Meeting 2024 Editor's Cut Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and…
- benzinga.com Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per…
- benzinga.com Lipocine Announces Distribution And License Agreement With SPC Korea To Commercialize TLANDO In South Korea Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development…
- benzinga.com Lipocine Reports Data From Its qEEG Study Of Its Oral Brexanolone, A Proprietary Bioidentical NAS Being Developed For The Treatment Of Post-partum Depression - Filing The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABAA positive…
benzinga.com Lipocine Announces Supply And Distribution Agreement With Pharmalink To Commercialize TLANDO In The Gulf Cooperation Council Countries Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply…- benzinga.com Alliance Global Partners Initiates Coverage On Lipocine with Buy Rating, Announces Price Target of $10 Alliance Global Partners analyst Scott Henry initiates coverage on Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $10.
- benzinga.com Lipocine Announces Phase 2 Data On LPCN 2401 To Be Presented At ObesityWeek November 3 – 6, 2024 Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbiditySALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc.…
- benzinga.com Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(0.78) Estimate, Sales $89.565K Miss $290.000K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.78) by 28.21 percent. This is a 17.65 percent increase over losses of $(0.68)…
- benzinga.com Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing, Targeting Q4 2024 Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞Ctrough criterion was metLPCN 1154 was well tolerated with no sedation or somnolence events observedOn track for NDA filing, targeted…